The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 28th 2025
From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.
Model Could Help Screen NSCLC Patients Likely to Benefit From Anti–PD-L1 Immunotherapy
January 19th 2022A model developed by researchers in China could help identify patients with non–small cell lung cancer (NSCLC) most likely to benefit from anti– programmed death-ligand 1 (PD-L1) immunotherapy.
Read More
Polypharmacy Linked With Rehospitalization, Death Among Patients With HF
January 19th 2022An analysis conducted in Japan among patients with acute decompensated heart failure (HF) revealed excessive polypharmacy at hospital discharge is associated with an increased risk of mortality after 1 year.
Read More
Study Highlights Health, Economic Benefits of RSV Vaccine for Older Adults
January 19th 2022With no existing respiratory syncytial virus (RSV) vaccine yet, researchers found that a vaccine comparable with the influenza vaccine could prevent tens of thousands of hospitalizations and deaths per year.
Read More
Phase 3 Data for Pembrolizumab in Hepatocellular Carcinoma Show Significant Improvements in OS, PFS
January 18th 2022Merck had previously received accelerated approval for pembrolizumab for patients with advanced hepatocellular carcinoma (HCC); an FDA panel left the approval in place while waiting on results from KEYNOTE-394.
Read More
CYNK-101 Receives Fast Track Designation for HER2-Positive Gastric/GEJ Cancers
January 18th 2022Natural killer cell therapy CYNK-101 was granted fast track designation by the FDA to treat HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with standard chemotherapy, trastuzumab, and pembrolizumab.
Read More
Understanding Real-World Trends in MRD Testing as Part of MM Management
January 18th 2022An abstract presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition assessed real-world data on patients with multiple myeloma to provide insight into longitudinal testing patterns and rates of sustained minimal residual disease (MRD) negativity.
Read More
MRD Kinetics Identify High-risk CLL in Study of Zanubrutinib, Venetoclax, Obinutuzumab
January 16th 2022An abstract presented at the 63rd American Society of Hematology Meeting & Exposition found that the regimen was effective and that MRD could potentially be used as a biomarker to inform treatment duration.
Read More
Patients Typically Satisfied With Outcomes of Surgery for Hidradenitis Suppurativa
January 15th 2022Self-reported experiences among the patients showed that 76% of patients were extremely or very satisfied with their surgery and 58% of patients were satisfied with the appearance of their healed wound, despite a recurrence rate of 41%.
Read More
Genomic Profiling for NSCLC Improves Survival Outcomes With Modest Budget Impact
January 14th 2022An increase in the use of comprehensive genomic profiling among patients with advanced non–small cell lung cancer (NSCLC) was associated with additional life-years gained and a low-cost budget impact.
Read More
Two-Year OS Doubles for Patients With Philadelphia-Positive Relapsed ALL After HSCT
January 12th 2022While acute lymphoblastic leukemia (ALL) was still the primary cause of death, researchers saw a steady increase in 2-year survival from 27.8% to 54.8% even as patient age at the time of relapse after allogeneic hematopoietic stem cell transplantation (HCST) increased.
Read More